Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
Clinical and Molecular Hepatology. 2018;24(4):351-357 
P2-154: Efficacy of hepatitis B virus vaccination in genotype 4 chronic hepatitis C patients achieved sustained virologic response with direct acting antivirals
Journal of Viral Hepatitis. 2018;25:182-183
P1-096: Eradication of chronic hepatitis C infection with direct acting antivirals is associated with reduction in fibrosis by Transient Elastography (FibroScan)
Journal of Viral Hepatitis. 2018;25:73-73
P1-107: Safety and efficacy of direct acting antivirals in genotype 4 chronic hepatitis C elderly patients, a pilot study
Journal of Viral Hepatitis. 2018;25:78-79
Direct-Acting Antivirals in Chronic Hepatitis C Infection with Liver Cirrhosis
Hepatitis B and C [Working Title]. 2019;
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease
Liver International. 2018;38(12):2137-2148
Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
Scientifica. 2012;2012:1-22
Efficacy and Safety of Second-Generation Direct Acting Antivirals for Chronic Hepatitis C in Patients with Advanced Renal Failure
American Journal of Kidney Diseases. 2017;69(4):A21
New direct-acting antivirals' combination for the treatment of chronic hepatitis C
Liver International. 2011;31:68-77
P1-078: Efficacy and safety of pan-genotypic direct acting antivirals (DAAs) in genotype 3 chronic hepatitis C (CHC): a systematic review and meta-analysis
Journal of Viral Hepatitis. 2018;25:62-63